Naproxen/esomeprazole
| Combination of | |
|---|---|
| Naproxen | NSAID |
| Esomeprazole | Proton pump inhibitor |
| Clinical data | |
| Trade names | Vimovo |
| AHFS/Drugs.com | Professional Drug Facts |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Naproxen/esomeprazole, sold under the brand name Vimovo, is a pain reliever medication in the form of a tablet for oral consumption, containing naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and a delayed release formulation of esomeprazole, a stomach acid–reducing proton-pump inhibitor (PPI).[2][3] It is produced by AstraZeneca.[4] Vimovo is US Food and Drug Administration approved for use against osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[2] It is intended to decrease the risk of gastric ulcers from treatment with NSAIDs.[2]
It is available as a generic medication.[5] In 2020, it was the 390th most commonly prescribed medication in the United States, with more than 300 thousand prescriptions.[6][7]
Adverse effects
|
See also: Naproxen § Adverse effects, and Esomeprazole § Adverse effects |
Society and culture
Economics
Vimovo was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to Vimovo".[3]
In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo.[8] According to The Atlantic, "since 2014, Horizon Pharma's net sales have been more than $455 million".[8]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
